AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

A Study Comparing the Necessity of a Second Transurethral Resection in High-Risk Non-Muscle-Invasive Bladder Cancer Patients With Negative Results From Post-Initial Resection Urine Genome-Wide Low-Depth Sequencing

RecruitingNAAges 18 Years - 80 YearsAllThe First Affiliated Hospital with Nanjing Medicaโ€ฆ
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This study is a prospective, randomized, multicenter clinical trial aiming to enroll 428 patients with non-muscle-invasive bladder cancer (NMIBC) from the Department of Urology at Jiangsu Provincial People's Hospital and its affiliated centers, who have undergone their initial transurethral resection and are scheduled for a second resection. Within 1-6 weeks after the first resection and prior to the second resection, 100ml of routine urine will be collected and sent within 24 hours to Beijing Genetron Health Clinical Laboratory Co., Ltd. for the extraction of urinary sediment DNA, which will then undergo genome-wide low-depth sequencing. Patients with positive test results will proceed with the second resection, while those with negative results will be randomly assigned in a 1:2 ratio to either the intervention group, which will not undergo a second resection, or the control group, whi

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Patients with NMIBC who have completed the initial transurethral resection and are scheduled for a second resection, as recommended by guidelines or physician's choice: 1. Incomplete initial TURBT due to various reasons (including large tumor size, high risk of intraoperative bleeding, extensive tumor range, etc.), posing a risk of residual tumor; 2. Absence of muscle layer tissue in the initial resection specimen; 3. Post-initial resection pathology indicating T1 stage; 4. Post-initial resection pathology indicating G3/high-grade tumor, excluding pure carcinoma in situ; * Ability to provide a 100ml routine urine sample within 1-6 weeks after the initial resection and before the second resection; * Age โ‰ฅ 18 years; * Willingness to provide basic clinical information, pathology, and subsequent - recurrence monitoring results; * Willingness to sign the informed consent form. Exclusion Criteria: * Patients with other non-urothelial malignant tumors (including prostate cancer and renal cell carcinoma); * Patients previously diagnosed with muscle-invasive bladder cancer; * Patients unable to undergo a second resection; * Patients with incomplete pathological information of the sample; * Patients with contaminated samples; * Patients whose urine samples fail quality control for valid reasons and cannot be resampled; * Any condition deemed by the investigator as potentially harming the subject or preventing the subject from meeting or fulfilling the study requirements; * Patients unable to provide written informed consent.
๐Ÿ’Š

What it tests

  • Urine biomarker -Guided without reTURBT
๐Ÿ“

Where

1 site
The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029
Nanjing, China
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy